Home/Filings/4/0001213900-25-033144
4//SEC Filing

Papapetropoulos Spyros 4

Accession 0001213900-25-033144

CIK 0001191070other

Filed

Apr 17, 8:00 PM ET

Accepted

Apr 18, 8:04 AM ET

Size

5.9 KB

Accession

0001213900-25-033144

Insider Transaction Report

Form 4
Period: 2025-04-16
Papapetropoulos Spyros
DirectorPresident and CEO
Transactions
  • Award

    Employee Stock Option (Right-to-Buy)

    2025-04-16$5.16/sh+270,000$1,393,200282,529 total
    Exercise: $5.16Exp: 2035-04-16Common Stock (270,000 underlying)
Footnotes (1)
  • [F1]Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested.

Issuer

Neuphoria Therapeutics Inc.

CIK 0001191070

Entity typeother

Related Parties

1
  • filerCIK 0001832694

Filing Metadata

Form type
4
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 8:04 AM ET
Size
5.9 KB